All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% stage M1A stage M1B
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - L2 - all population, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96]
KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
0.73 [0.64 ; 0.84 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,831 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.57 ; 0.81 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable PFS (extension)detailed results KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.53 ; 0.70 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64]
KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.56 [0.50 ; 0.63 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,831 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80]
KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
4.51 [3.21 ; 6.32 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 29% 1,831 moderate not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.65 [0.46 ; 0.92 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26]
KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
0.96 [0.61 ; 1.51 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 75% 1,766 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91]
KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
0.66 [0.48 ; 0.89 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 37% 1,766 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.40 [0.23 ; 8.60 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87]
KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.05 [0.74 ; 1.50 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76]
KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.92 [0.84 ; 4.37 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88]
KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81]
KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.25 [0.05 ; 1.30 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 36% 1,766 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.19 ; 4.70 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48]
KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.57 [0.15 ; 2.25 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13]
KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
0.38 [0.15 ; 0.93 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 33% 1,766 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81]
KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17]
KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
0.71 [0.35 ; 1.44 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10]
KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11]
KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.35 [0.15 ; 0.82 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
3.18 [0.85 ; 11.84 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.63 [0.10 ; 3.88 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.58 [0.13 ; 2.67 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.16 [0.18 ; 7.66 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17]
KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17]
0.07 [0.01 ; 0.50 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 2 0% 699 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.09 [0.22 ; 5.44 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50]
KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.94 [0.22 ; 4.02 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.29 [0.07 ; 1.29 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39]
KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.18 [0.04 ; 0.96 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
1.42 [0.11 ; 18.63 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 2 0% 699 moderate not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.63 [0.10 ; 3.88 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29]
KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32]
0.24 [0.03 ; 2.13 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 2 0% 699 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90]
KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.52 [0.32 ; 7.22 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.13 ; 6.69 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24]
0.18 [0.03 ; 1.07 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 2 0% 699 moderate not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.17 [0.18 ; 7.68 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69]
0.96 [0.06 ; 15.38 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015 2 0% 699 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.03; 2.13]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.38 [0.10 ; 1.43 ] KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,766 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 13:46 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 69
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
